Prime Medicine, Inc. 8-K

What Happened
Prime Medicine, Inc. announced its financial results and business highlights for the year ended December 31, 2025 by press release dated March 3, 2026 (furnished as Exhibit 99.1 to the Form 8-K). On the same date the company posted an updated corporate presentation to its investor webpage (furnished as Exhibit 99.2 and disclosed under Regulation FD). The Form 8-K was signed by CEO Allan Reine, M.D.

Key Details

• Filing date: March 3, 2026; reporting period: year ended December 31, 2025.
• Press release announcing results and business highlights: Exhibit 99.1.
• Updated corporate presentation posted to the company investor site (Exhibit 99.2); referenced under Item 7.01 (Regulation FD disclosure).
• Cover page interactive data (Inline XBRL) included as Exhibit 104.

Why It Matters
This 8-K delivers the company’s official year‑end results and investor materials — primary sources for reviewing Prime Medicine’s recent performance and strategic updates. Investors should review the furnished press release and corporate presentation (Exhibits 99.1 and 99.2) for detailed financial figures, operational highlights, and any management commentary announced on March 3, 2026. The Regulation FD notice indicates the presentation was made public to ensure fair disclosure to the market.